More than 330 healthcare organizations collectively urged the US government to extend telehealth prescribing flexibility introduced during the pandemic to continue access to critical healthcare.
The DEA's leaked proposed rule threatens to restrict telehealth prescriptions for Schedule II drugs, such as ADHD and opioid medications, unless an in-person visit occurs.
If the telehealth prescribing flexibility is not extended, millions could potentially lose access to necessary treatments, as evidenced by the increased reliance on flexible prescribing since 2020.
While Schedule III-V drugs may still be prescribed via telehealth after in-person visits, the proposed rule represents a significant setback for telehealth advocates and patients.
Collection
[
|
...
]